Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Intellia Therapeutics says its CRISPR-based treatment succeeds in ...
Intellia seeks FDA nod after phase 3 CRISPR success
Intellia Therapeutics stock is down nearly 95% from its record highs ...
Intellia Therapeutics Announces First Quarter 2026 Financial Results ...
Intellia in the spotlight: Earnings test follows CRISPR milestone By ...
Intellia Therapeutics launches $150M public stock offering
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs ...
Intellia seeks FDA approval for in vivo CRISPR therapy
Intellia Therapeutics prices $180M stock offering at discount
Intellia Therapeutics, Inc. (NTLA) expected to beat earnings estimates ...
Intellia Therapeutics Lodges A First In Gene Editing; Why Are Analysts ...
Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) First-Quarter Results Just ...
Intellia Therapeutics (NTLA) Is Down 15.1% After Phase 3 lonvo-z Data ...
Intellia Therapeutics stock gains — FDA lifts clinical hold on pivotal ...
Intellia rises as FDA lifts clinical hold (NTLA:NASDAQ) | Seeking Alpha
Why The Narrative Around Intellia Therapeutics (NTLA) Is Shifting After ...
Intellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins ...
Intellia files CRISPR drug after historic phase 3 readout | pharmaphorum
Intellia Therapeutics Shares Slip Despite Strong Phase 3 Data
Intellia data spark debate about CRISPR drug’s potential
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Intellia Therapeutics (NTLA) Investor Relations & Financial Reports
Premarket Movers Monday: Intellia Therapeutics, Boeing, Nvidia - TheStreet
Intellia Therapeutics-Aktie unter 50-Tage-Linie - boerse.de
Intellia Therapeutics Emerges as a Leading Force in Gene Editing ...
Intellia Therapeutics' Lonvo-z: A Gene-Editing Breakthrough for HAE and ...
Intellia Therapeutics' Momentum in ATTR-CM and HAE Trials: A Catalyst ...
Intellia cleared by FDA to start Phase 3 test of gene editing treatment ...
Intellia filing spurs safety concerns over CRISPR drug | BioPharma Dive
Intellia launches AI-driven vetting and project delivery platform - Wamda
Intellia Therapeutics Doses First Patient in Landmark
Intellia pauses two CRISPR drug studies after safety scare | BioPharma Dive
Intellia Therapeutics Resumes Gene Therapy Trial for Rare Nerve Disease ...
Intellia trumpets CRISPR drug data, but shares fall | pharmaphorum
Intellia Therapeutics Receives Partial FDA Clearance for Key Trial
Patient in Intellia CRISPR trial dies after being hospitalized with ...
What Makes Intellia Therapeutics (NTLA) an Interesting Investment ...
Intellia Therapeutics Pauses ATTR Amyloidosis Trials Amid Patient Death ...
Is Intellia Therapeutics Attractive After a 70.6% Drop and Latest ...
CRISPR biotech Intellia cuts staff as it eyes 2027 launch | pharmaphorum
Intellia Therapeutics Stock Plummets After Adverse Event In Gene ...
Intellia Therapeutics Shares Plunge on Clinical Trial Setbacks
Find A Distributor Blog CM Labs Intellia Instructor - Find A ...
Why Cathie Wood's Recent Accumulation of Intellia Therapeutics (NTLA ...
Intellia Therapeutics, Inc. (NTLA) Stock: Plunges 43% After Phase 3 ...
Intellia Therapeutics Shares Plunge on Clinical Trial Setback
Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 ...
Turning Emerging Markets Into Consultancy Hotspots With Intellia
Intellia Completes Enrollment in Global Phase 3 HAELO Study of Lonvo-z ...
Intellia Therapeutics (NTLA) Surges 13.10% on ARK ETFs' $2.47M Stake in ...
Intellia Completes Phase 3 HAE Trial Enrollment, 2026 Data Expected ...
Intellia Therapeutics Shares Plummet Following FDA Clinical Hold | NewsCase
Intellia Therapeutics Achieves Key Milestones in HAE Study - Investors ...
Intellia Therapeutics Shares Plunge Following Clinical Trial Setback
Intellia Therapeutics Faces Regulatory Halt as Stock Defies Expectations
Is Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene ...
Intellia Therapeutics Receives Regulatory Clearance to Resume Key Trial
Intellia now has the data for No. 1 unanswered gene editing question ...
Intellia on LinkedIn: Intellia
Intellia Therapeutics Faces Mounting Pressure Following Clinical Trial ...
Intellia Therapeutics’ Long-Term Study of NTLA-2001: What Investors ...
Why Intellia Therapeutics, Inc.’s (NTLA) Stock Is Up 6.31% | AAII
Intellia doesn't need to re-dose NTLA-2001. But it can be done
Intellia Therapeutics Faces Regulatory Crisis as Clinical Trial Halted
The Intellia Therapeutics IPO - Editas vs. Intellia - Nanalyze
CRISPR biotech Intellia plummets as trial paused for safety | pharmaphorum
New Intellia Instructor Training Management Solution from CM Labs ...
Intellia Therapeutics Investors Await Critical FDA Verdict
Gene-editing Company Intellia Therapeutics Files for a $120 Million IPO ...
Intellia Therapeutics, Inc. 2023 Q1 - Results - Earnings Call ...
Intellia Therapeutics Optimizes Office Space in Cambridge and Waltham ...
Intellia Therapeutics Shares Struggle to Regain Footing Amid Regulatory ...
Intellia value halved by Phase III nex-z trials pause | The Pharmaletter
Intellia Therapeutics Faces Severe Setback Following Clinical Trial ...
Intellia Therapeutics Shares Plummet After Clinical Trial Halt and ...
Intellia pauses phase 3 CRISPR trials after patient is hospitalized ...
Dan Lev – Intellia Therapeutics - Vanguard Law Magazine
Intellia Therapeutics (NTLA) Stock Crashes 46% After Company Halts Gene ...
Intellia Therapeutics Faces Regulatory Hurdle While Advancing ...
Intellia Therapeutics Reports 97% Attack- & LTP-Free in HAE | NTLA ...
Intellia Therapeutics, building exterior, Cambridge, Massachusetts, USA ...
Intellia Therapeutics Faces Investor Scrutiny Amid Clinical Trial ...
Intellia Doses First Patient in Phase 3 CRISPR Gene Editing Trial for ...
Intellia seeks to broaden gene editing’s potential with full-spectrum ...
BioCentury - Intellia delivers transformative potential with in vivo ...
Intellia Therapeutics Posts More Data on its Gene Editing Program ...
Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical ...
Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough ...
Gene Editing Pioneer Intellia Therapeutics Delivers Landmark Clinical ...
In Major CRISPR Milestone, Intellia Successfully Edits Genes Inside ...
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Intellia Therapeutics Leads Gene-Editing Stock Rally - TheStreet
Intellia's In Vivo CRISPR Drug Slashes Swelling Attacks in Phase III ...
NTLA Q1 2026 Earnings Report on 5/11/2026
Cathie Wood's ARK Invest Dumps Rocket Lab (RKLB) While Loading Up on ...
Intellia's one-time CRISPR therapy shows strong Phase 3 results
NTLA stock rises 20% in 3 months: Here's what you should know
凯西·伍德旗下ARK减持AMD股票，买入Tempus AI及Intellia 提供者 Investing.com
Intellia: Nex-z-Stopp aufgehoben, Lonvo-z 87% Erfolg
Intellia：募资1.5亿美元，并递交体内CRISPR基因编辑疗法上市申请|基因编辑_新浪财经_新浪网
Intellia: lonvo-z-Antrag im April eingereicht
NTLA Q1 earnings beat estimates, revenues miss mark, pipeline in focus
Medicaid pilot, Intellia, UniQure: Readout Newsletter
FinancialContent - Intellia, the financial analyst cloud unlocking ...
Get Me (DNA) Rewrite: Intellia’s First Acquisition Expands CRISPR Toolkit
Intellia’s CRISPR drug could offer one-shot HAE treatment | pharmaphorum
CM Labs Simulations Unveils Intellia: Intelligent Training System for ...
Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA
Intellia's 2 gene editing therapies both see early successes
Intellia, with first results, delivers a 'landmark' for CRISPR gene ...
Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment ...
.jpg?VersionId=CpVfBYRi_P20fnX_IsaeSDtHL5CG.zA.)
